Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

NW Clarke; A Ali; FC Ingleby ORCID logo; A Hoyle; CL Amos; G Attard; CD Brawley; J Calvert; S Chowdhury; A Cook; +41 more... W Cross; DP Dearnaley; H Douis; D Gilbert; S Gillessen; RJ Jones; RE Langley; A MacNair; Z Malik; MD Mason; D Matheson; R Millman; CC Parker; AWS Ritchie; H Rush; JM Russell; J Brown; S Beesley; A Birtle; L Capaldi; J Gale; S Gibbs; A Lydon; A Nikapota; A Omlin; JM O'Sullivan; O Parikh; A Protheroe; S Rudman; NN Srihari; M Simms; JS Tanguay; S Tolan; J Wagstaff; J Wallace; J Wylie; A Zarkar; MR Sydes; MKB Parmar; ND James; STAMPEDE investigators; (2020) Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. ANNALS OF ONCOLOGY, 31 (3). 442-. ISSN 0923-7534 DOI: 10.1016/j.annonc.2020.01.002
Copy

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.


picture_as_pdf
PIIS0923753420359202.pdf
subject
Published Version
Available under Creative Commons: NC-ND 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads